These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26824643)

  • 21. NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids.
    Simeth NA; Bause M; Dobmeier M; Kling RC; Lachmann D; Hübner H; Einsiedel J; Gmeiner P; König B
    Bioorg Med Chem; 2017 Jan; 25(1):350-359. PubMed ID: 27842797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues.
    Sefler AM; He JX; Sawyer TK; Holub KE; Omecinsky DO; Reily MD; Thanabal V; Akunne HC; Cody WL
    J Med Chem; 1995 Jan; 38(2):249-57. PubMed ID: 7830267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based exploration of an allosteric binding pocket in the NTS1 receptor using bitopic NT(8-13) derivatives and molecular dynamics simulations.
    Kling RC; Burchardt C; Einsiedel J; Hübner H; Gmeiner P
    J Mol Model; 2019 Jun; 25(7):193. PubMed ID: 31209646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced peptide bond pseudopeptide analogues of neurotensin.
    Doulut S; Rodriguez M; Lugrin D; Vecchini F; Kitabgi P; Aumelas A; Martinez J
    Pept Res; 1992; 5(1):30-8. PubMed ID: 1623301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1,2,3-Triazole Stabilized Neurotensin-Based Radiopeptidomimetics for Improved Tumor Targeting.
    Mascarin A; Valverde IE; Vomstein S; Mindt TL
    Bioconjug Chem; 2015 Oct; 26(10):2143-52. PubMed ID: 26347939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationships of neuropeptide FF and related peptidic and non-peptidic derivatives.
    Vyas N; Mollereau C; Chevé G; McCurdy CR
    Peptides; 2006 May; 27(5):990-6. PubMed ID: 16490282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of the N-terminal part of peptidic selective NPFF₂ agonists.
    Mazarguil H; Mollereau C; Czaplicki G; Zajac JM
    Peptides; 2012 Sep; 37(1):157-60. PubMed ID: 22813580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8-13).
    Sousbie M; Vivancos M; Brouillette RL; Besserer-Offroy É; Longpré JM; Leduc R; Sarret P; Marsault É
    J Med Chem; 2018 Aug; 61(16):7103-7115. PubMed ID: 30035538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurotensin analogs by fluoroglycosylation at N
    Schindler L; Wohlfahrt K; Gluhacevic von Krüchten L; Prante O; Keller M; Maschauer S
    Sci Rep; 2022 Sep; 12(1):15028. PubMed ID: 36056076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of neurotensin and opioid receptors in the cardiorespiratory effects of [Ile⁹]PK20, a novel antinociceptive chimeric peptide.
    Kaczyńska K; Szereda-Przestaszewska M; Kleczkowska P; Lipkowski AW
    Eur J Pharm Sci; 2014 Oct; 63():8-13. PubMed ID: 25008116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand.
    Held C; Plomer M; Hübner H; Meltretter J; Pischetsrieder M; Gmeiner P
    ChemMedChem; 2013 Jan; 8(1):75-81. PubMed ID: 23097347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues.
    Kokko KP; Hadden MK; Orwig KS; Mazella J; Dix TA
    J Med Chem; 2003 Sep; 46(19):4141-8. PubMed ID: 12954066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226.
    Mollereau C; Gouardères C; Dumont Y; Kotani M; Detheux M; Doods H; Parmentier M; Quirion R; Zajac JM
    Br J Pharmacol; 2001 May; 133(1):1-4. PubMed ID: 11325787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo behavioral effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier.
    Kokko KP; Hadden MK; Price KL; Orwig KS; See RE; Dix TA
    Neuropharmacology; 2005 Mar; 48(3):417-25. PubMed ID: 15721174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radical arylation of tyrosine and its application in the synthesis of a highly selective neurotensin receptor 2 ligand.
    Pratsch G; Unfried JF; Einsiedel J; Plomer M; Hübner H; Gmeiner P; Heinrich MR
    Org Biomol Chem; 2011 May; 9(10):3746-52. PubMed ID: 21472182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
    Cabrele C; Beck-Sickinger AG
    J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane β-amino acids shifts selectivity toward the Y(4) receptor.
    Berlicki L; Kaske M; Gutiérrez-Abad R; Bernhardt G; Illa O; Ortuño RM; Cabrele C; Buschauer A; Reiser O
    J Med Chem; 2013 Nov; 56(21):8422-31. PubMed ID: 24090364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular recognition of the NPY hormone family by their receptors.
    Lindner D; Stichel J; Beck-Sickinger AG
    Nutrition; 2008 Sep; 24(9):907-17. PubMed ID: 18725086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor.
    Georgsson J; Sköld C; Botros M; Lindeberg G; Nyberg F; Karlén A; Hallberg A; Larhed M
    J Med Chem; 2007 Apr; 50(7):1711-5. PubMed ID: 17358051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological activities of psi (CH2NH) pseudopeptide analogues of the C-terminal hexapeptide of neurotensin.
    Couder J; Tourwé D; Van Binst G; Schuurkens J; Leysen JE
    Int J Pept Protein Res; 1993 Feb; 41(2):181-4. PubMed ID: 8458692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.